Neurophysiological studies provide valuable insights into the cortical and subcortical dysfunction underlying corticobasal syndrome (CBS). Electroencephalography (EEG), evoked potentials, and electromyography (EMG) findings help differentiate CBS from other parkinsonian syndromes, assess disease severity, and may serve as biomarkers for clinical trials. Unlike structural MRI or PET imaging, neurophysiology captures real-time functional activity of neural circuits, offering unique perspectives on network dysfunction in CBS[@kostopoulos2022, @stangelova2023].
EEG abnormalities in CBS reflect cortical dysfunction secondary to tau pathology affecting frontoparietal regions. The pattern differs from both Parkinson's disease and progressive supranuclear palsy:
| Feature | CBS Finding | Comparison with PSP | Comparison with PD |
|---|---|---|---|
| Background rhythm | Generalized slowing, especially in frontal regions | Similar but more severe | Preserved alpha until advanced stages |
| Regional asymmetry | Asymmetric slowing (contralateral to most affected side) | Less pronounced asymmetry | Typically symmetric |
| Alpha frequency | 7-9 Hz (borderline theta) | 8-10 Hz | 9-11 Hz |
| Theta/delta activity | Prominent frontal intermittent rhythmic delta activity (FIRDA) | More prominent | Less common |
| Focal slowing | Frontal and parietal slowing | Parieto-occipital in PSP | Variable |
The asymmetric EEG pattern in CBS reflects the characteristic unilateral cortical involvement that distinguishes it from most other neurodegenerative disorders. This lateralization correlates with the clinical asymmetry of motor and cognitive symptoms[@nishioka2021].
FIRDA is frequently observed in CBS, particularly in moderate to advanced disease:
Rare in CBS but reported in advanced cases:
Quantitative EEG analysis provides objective measures for tracking disease progression:
| Parameter | CBS Value | Normal Controls | Clinical Correlation |
|---|---|---|---|
| Mean dominant frequency | 7.2 ± 1.2 Hz | 9.5 ± 1.0 Hz | Disease duration |
| Relative theta power | 35-45% | 15-20% | Cognitive impairment |
| Relative alpha power | 15-25% | 55-65% | Cortical involvement |
| Theta/alpha ratio | 2.5-4.0 | 0.5-0.8 | Executive dysfunction |
| Interhemispheric coherence | Reduced (0.4-0.6) | 0.7-0.8 | Callosal degeneration |
qEEG parameters correlate with clinical measures including MoCA scores and disease duration, suggesting potential utility as progression biomarkers[@chen2023].
SSEPs are particularly valuable in CBS due to the prominent cortical sensory dysfunction:
| SSEP Parameter | CBS Finding | Diagnostic Value |
|---|---|---|
| N20 amplitude | Increased (giant) | Differentiates CBS from PSP (high sensitivity) |
| Central conduction time | Prolonged | Correlates with cortical sensory loss |
| Interhemispheric difference | Significant (>50%) | Reflects asymmetric pathology |
Transcranial magnetic stimulation (TMS) reveals cortical hyperexcitability:
| Parameter | CBS | PSP | CBD |
|---|---|---|---|
| Motor threshold | ↓↓ | Normal | ↓ |
| MEP amplitude | ↑↑ | Normal | ↑ |
| Cortical silent period | ↓↓ | Normal | ↓ |
| Intracortical inhibition | ↓↓ | Normal | ↓ |
The findings suggest loss of GABAergic inhibition in CBS motor cortex, distinguishing it from PSP where these parameters remain relatively preserved[@kobayashi2019].
VEP findings in CBS are less pronounced than in PSP:
Routine motor/sensory nerve conduction studies are typically normal in CBS, distinguishing it from peripheral neuropathies. However:
Cortical myoclonus is common in CBS (40-60% of patients):
| Feature | Finding | Implication |
|---|---|---|
| Distribution | Focal, asymmetric | Correlates with cortical pathology |
| Stimulus sensitivity | Sensitive to sudden sounds or touch | Cortical origin |
| EMG burst duration | < 50 ms (cortical) | Differentiates from subcortical myoclonus |
| EEG correlation | Time-locked cortical discharge | Confirms cortical origin |
Neurophysiological measures are being evaluated as biomarkers:
| Parameter | Utility | Limitations | Status |
|---|---|---|---|
| qEEG theta/alpha ratio | Progression marker | Non-specific | Validated |
| SSEP amplitude | Diagnostic | Requires expertise | Clinical use |
| TMS cortical excitability | Mechanism | Variability | Research |
| Myoclonus EMG | Diagnostic | Subjective | Clinical |
| MEP threshold | Treatment response | Device-dependent | Research |
Neurophysiology complements other biomarker modalities:
Emerging neurophysiological technologies:
Neurophysiology helps differentiate CBS from mimicking conditions:
| Finding | CBS | PSP |
|---|---|---|
| SSEP giant potentials | 60-70% | 10-20% |
| Asymmetric EEG slowing | Common | Less common |
| MEP hyperexcitability | Marked | Mild |
| Finding | CBS | PD |
|---|---|---|
| EEG slowing | Prominent | Late, mild |
| SSEP | Giant potentials rare | Normal |
| Cortical inhibition | Impaired | Preserved |
| Finding | CBS | AD |
|---|---|---|
| Regional EEG pattern | Frontal > posterior | Posterior > frontal |
| Asymmetry | Prominent | Symmetric |
| Myoclonus (EMG) | Common | Less common |